Table 2 Clinical and parasitological efficacy of the five antimalarial drug combinations
Artesunate-amodiaquine N = 360 | Artesunate-mefloquine N = 145 | Artemether-lumefantrine (four doses) N = 140 | Artemether-lumefantrine (six doses) N = 149 | Amodiaquine-sulphadoxine-pyrimethamine N = 161 | |
|---|---|---|---|---|---|
Parasitological failure, day14 | 0% | 0% | 0% | 0% | 0% |
Clinical failure, day14 (n) | 0% | 0% | 0.7% (1) | 0% | 0% |
ACPR, day 14 | 100% | 100% | 99.3% | 0% | 100% |
Gametocyte carriage, day 14 | 0% | 0% | 0% | 3% | 0% |
Parasitological failure, day 21 | 0% | 0% | 0% | 0% | 0% |
Clinical failure, day 21 (n) | 1.4% (5) | 0.7% (1) | 3.6% (5) | 0% | 0.6% (1) |
ACPR, day 21 | 98.6% | 99.3% | 96.4% | 0% | 99.4% |
Gametocyte carriage, day 21 | 0% | 0% | 0% | 0% | 0% |
Parasitological failure, day 28 (n) | 0.8% (3) | 0% | 1.4% (2) | 0% | 0% |
Clinical failure, day 28 (n) | 0.3% (1) | 1.4% (2) | 11.4% (16) | 0% | 0.6% (1) |
ACPR, day 28 | 97.5% | 97.9% | 82.8% | 0% | 98.7% |
Gametocyte carriage, day 28 | 0% | 0% | 0% | 0% | 0% |
ACPR, day 28 after PCR | 100% | 100% | 96.4% | 100% | 100% |
ACPR, day 42 (30% of patients) | 100% | 100% | 100% | 100% | 100% |